Habeas corpus

With the close of a $60 million financing tranche earlier this year, CovX Pharmaceuticals Inc. has quietly raised a total of $105 million from Tavistock Life Sciences since it was founded in 2002. For a company with that much funding, CovX has disclosed very little about what it's up to. Now, with a new focus on cancer and a candidate slated to enter the clinic next year, the company is starting to come out of its shell.

According to CSO Rodney Lappe, the key to the company's CovX-Body technology is its ability to use a single antibody as a scaffold on which to build all of its product candidates. In addition to the "economies of scale" created by using the same antibody for each CovX-Body, he said, the candidates are equipped with the long half-life and bivalency advantages of an antibody along with the potency of a peptide or small molecule...